Literature DB >> 34484954

Upper Gastrointestinal Tract Lymphoma With Natalizumab: Evidence of Impaired Immune Surveillance?

Lauren Gomes1, Emily Watson1, Matthew Robert Smith1, Edward Morris1, Mike Boggild1.   

Abstract

Entities:  

Year:  2021        PMID： 34484954      PMCID： PMC8382421          DOI： 10.1212/CPJ.0000000000000985

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

1.  Natalizumab-associated complication? First case of peripheral T cell lymphoma.

Authors:  Jeffrey Schowinsky; John Corboy; Timothy Vollmer; B K Kleinschmidt-DeMasters
Journal:  Acta Neuropathol       Date:  2012-03-11       Impact factor: 17.088

2.  Immunosuppression and malignancy.

Authors: 
Journal:  Br Med J       Date:  1972-09-23

Review 3.  Monoclonal Antibodies for Multiple Sclerosis: An Update.

Authors:  Jonas Graf; Orhan Aktas; Konrad Rejdak; Hans-Peter Hartung
Journal:  BioDrugs       Date:  2019-02       Impact factor: 5.807

4.  Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study.

Authors:  M Fallah; X Liu; J Ji; A Försti; K Sundquist; K Hemminki
Journal:  Ann Oncol       Date:  2014-07-31       Impact factor: 32.976

5.  Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab.

Authors:  Jennie Y Law; Dong W Kim; Ariel Sturgis; Harris V Naina
Journal:  Clin Med Insights Oncol       Date:  2015-07-01

6.  Glioblastoma in natalizumab-treated multiple sclerosis patients.

Authors:  Fabian Sierra Morales; Robert B Wright; Jorge E Novo; Leonidas D Arvanitis; Dusan Stefoski; Igor J Koralnik
Journal:  Ann Clin Transl Neurol       Date:  2017-06-06       Impact factor: 4.511

7.  Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.

Authors:  Jan W Traub; Hannah L Pellkofer; Katja Grondey; Ira Seeger; Christoph Rowold; Wolfgang Brück; Leila Husseini; Silke Häusser-Kinzel; Martin S Weber
Journal:  J Neuroinflammation       Date:  2019-11-16       Impact factor: 8.322
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.